SGLT-2 inhibitors may cut dementia risk in patients with diabetes
By
Haymarket Media
Sep 03, 2024
The findings show a greater effect with longer treatment, compared with dipeptidyl peptidase-4 inhibitors.
Is Eli Lilly using ‘granfluencers’ to raise awareness of its Alzheimer’s med?
By
Marc Iskowitz
Sep 04, 2024
Here’s why older internet celebs — granfluencers — soon might be making rounds on the Alzheimer’s drug marketing scene.
Cholinesterase inhibitors beneficial for dementia with Lewy bodies
By
Haymarket Media
Aug 28, 2024
The use of cholinesterase inhibitors significantly slowed cognitive decline at follow-ups compared with memantine and nonuse.
No spike in schizophrenia, other diagnoses among people with dementia after feds crack down on antipsychotic...
By
Kimberly Marselas
Aug 28, 2024
Federal policies designed to reduce use of antipsychotic medications in nursing homes did not lead to clinically significantly higher rates of schizophrenia diagnoses among people living with dementia,...
Risk for dementia similar with SGLT2 inhibitors, dulaglutide in T2DM
Aug 26, 2024
The estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults.